Compare
Inhibrx Biosciences, Inc. vs Scinai Immunotherapeutics Ltd. vs Outlook Therapeutics, Inc. vs Pluri Inc.
| Latest fiscal year | Inhibrx Biosciences, Inc. INBX | Scinai Immunotherapeutics Ltd. SCNI | Outlook Therapeutics, Inc. OTLK | Pluri Inc. PLUR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2026-06-30 |
| Revenue | $1.30M | $1.31M | $1.41M | $1.02M |
| Revenue growth (YoY) | +550.0% | +99.2% | n/a | -24.0% |
| Gross margin | n/a | -202.3% | 4.0% | 44.6% |
| Operating margin | n/m | -575.3% | n/m | n/m |
| Net margin | n/m | -633.6% | n/m | n/m |
| Net income | -$140.06M | -$8.31M | -$62.42M | -$23.82M |
| EPS (Diluted) | -$9.04 | n/a | -$1.79 | -$2.44 |
| Operating cash flow | -$129.79M | -$6.03M | -$51.83M | -$19.59M |
| Free cash flow | -$129.82M | -$6.05M | n/a | -$20.22M |
| Cash & equivalents | $124.22M | $1.66M | $8.08M | $3.53M |
| Total assets | $146.48M | $11.63M | $18.58M | $24.88M |
| Total liabilities | $138.49M | n/a | $50.77M | n/a |
| Shareholders' equity | $7.99M | $8.10M | -$32.19M | -$23.04M |
| Return on year-end equity | n/m | -102.5% | n/a | n/a |
| Shares outstanding | 14.58M | 13.87B | 53.89M | 10.82M |
Revenue, most recent five fiscal years
| Fiscal year | Inhibrx Biosciences, Inc. | Scinai Immunotherapeutics Ltd. | Outlook Therapeutics, Inc. | Pluri Inc. |
|---|---|---|---|---|
| Latest | $1.30M Ended 2025-12-31 | $1.31M Ended 2025-12-31 | $1.41M Ended 2025-09-30 | $1.02M Ended 2026-06-30 |
| 1 year earlier | $200.0K Ended 2024-12-31 | $658.0K Ended 2024-12-31 | n/a | $1.34M Ended 2025-06-30 |
| 2 years earlier | $1.80M Ended 2023-12-31 | n/a | n/a | $326.0K Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | n/a | $287.0K Ended 2023-06-30 |
| 4 years earlier | n/a | n/a | n/a | $234.0K Ended 2022-06-30 |